Abstract:
:A meta-analysis of 20 short term comparative studies of 5 selective serotonin reuptake inhibitors (SSRIs; citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) has shown no difference in efficacy between individual compounds but a slower onset of action of fluoxetine. There were suggestions that fluoxetine caused more agitation, weight loss and dermatological reactions than the other SSRIs. More patients discontinued fluvoxamine and fewer patients stopped sertraline because of adverse effects than their comparator SSRIs. The most common adverse reactions to the SSRIs were gastrointestinal (especially nausea) and neuropsychiatric (particularly headache and tremor). Data from the Committee on Safety of Medicines showed more reports of suspected reactions (including discontinuation reactions) to paroxetine, and of gastrointestinal reactions to fluvoxamine and paroxetine, than the other SSRIs during their first 2 years of marketing. Prescription-event monitoring revealed a higher incidence of adverse events related to fluvoxamine than its comparators. There were higher incidences of gastrointestinal symptoms, malaise, sedation and tremor during treatment with fluvoxamine and of sedation, tremor, sweating, sexual dysfunction and discontinuation reactions with paroxetine. Fluoxetine was not associated with a higher incidence of suicidal, aggressive and related events than the other SSRIs. Patients have survived large overdoses of each of the compounds, but concern has been expressed over 6 fatalities following overdoses of citalopram. Drug interactions mediated by cytochrome P450 enzymes are theoretically less likely to occur during treatment with citalopram and sertraline, but there is a sparsity of clinical data to support this. Methodological difficulties and price changes do not allow choice for recommendations on the choice of SSRI based on pharmacoeconomic data. Taking into account the strengths and weaknesses of the methods used to compare drugs, guidelines to the selection of individual SSRIs in clinical practice are proposed. Citalopram should be avoided in patients likely to take overdoses. Fluoxetine may not be the drug of first choice for patients in whom a rapid antidepressant effect is important or for those who are agitated, but it may have advantages over other SSRIs in patients who are poorly compliant with treatment and those who have previously had troublesome discontinuation symptoms. Fluvoxamine, and possibly paroxetine, should not be used as first choice in patients especially prone to SSRI-related adverse reactions, while paroxetine should be avoided if previous discontinuation of treatment was troublesome. When in doubt about the risks of drug interactions, citalopram or sertraline should be considered given the lower theoretical risk of interactions.
journal_name
Drugsjournal_title
Drugsauthors
Edwards JG,Anderson Idoi
10.2165/00003495-199957040-00005subject
Has Abstractpub_date
1999-04-01 00:00:00pages
507-33issue
4eissn
0012-6667issn
1179-1950journal_volume
57pub_type
杂志文章,meta分析相关文献
DRUGS文献大全abstract::Arrhythmia treatment has always been difficult, particularly as there are no good indicators of the optimal management strategy. The introduction of new antiarrhythmic agents has forced reappraisal of how these drugs are used. Dynamic electrocardiography and invasive electrophysiological studies are important tools fo...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198836050-00005
更新日期:1988-11-01 00:00:00
abstract::Numerous intervention studies have clearly demonstrated the value of antihypertensive treatment. By lowering diastolic blood pressure 5 to 6mm Hg in middle-aged hypertensive patients, a 42% reduction in stroke morbidity and a 14% reduction in coronary heart disease morbidity can be obtained. Recently published large i...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199300462-00008
更新日期:1993-01-01 00:00:00
abstract::Platinum-based doublet chemotherapy with or without bevacizumab is the standard of care for the initial management of advanced and metastatic non-small cell lung cancer (NSCLC) without a targetable molecular abnormality. However, the majority of patients with NSCLC will ultimately develop resistance to initial platinu...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0628-6
更新日期:2016-09-01 00:00:00
abstract::Antihistamines are a diverse group of drugs which possess the ability to inhibit various histaminic actions. By and large, they bear a certain structural resemblance to histamine, and act principally to prevent histamine-receptor interaction through competition with histamine for histamine receptors. Consequently, the...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197612040-00002
更新日期:1976-01-01 00:00:00
abstract::The corticosteroid mometasone and the long-acting β(2)-selective adrenoreceptor agonist formoterol have been combined in a single pressurized metered-dose inhaler for use in patients aged ≥12 years with asthma. In a 26-week well designed trial in patients with persistent asthma uncontrolled on medium-dose inhaled cort...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11206920-000000000-00000
更新日期:2012-06-18 00:00:00
abstract::ROS1 gene rearrangements exist in 1-2% of non-small cell lung cancers, typically occurring in younger, never or light smokers with adenocarcinoma. ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy. Crizotinib was the first tyrosine k...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01164-3
更新日期:2019-08-01 00:00:00
abstract::Acyclovir (aciclovir) is a nucleoside antiviral drug with antiviral activity in vitro against members of the herpes group of DNA viruses. As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of acyclovir provide significant therapeutic benefit in genita...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198937030-00002
更新日期:1989-03-01 00:00:00
abstract::Everolimus is an immunosuppressant that blocks growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells. Oral everolimus 0.75 or 1.5mg twice daily significantly reduced the incidence of the primary composite endpoint, efficacy failure 6 months after transplantation, compared with azathioprine...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200464080-00005
更新日期:2004-01-01 00:00:00
abstract::Bronchial asthma is an inflammatory disease. The characteristic pathological features of epithelial cell loss, goblet cell hyperplasia, increased deposition of collagen beneath the basement membrane, mast cell degranulation, and inflammatory cell infiltration of the mucosa are not limited to fatal asthma. Similar infl...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198900371-00021
更新日期:1989-01-01 00:00:00
abstract::Inhaled mometasone furoate (Asmanex) is a synthetic corticosteroid indicated for the first-line maintenance prophylactic therapy of persistent asthma in adults and adolescents. It is formulated for delivery via a breath-actuated dry powder inhaler (DPI) [Twisthaler].Inhaled mometasone furoate delivered by DPI is effec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666080-00011
更新日期:2006-01-01 00:00:00
abstract::The prevalence of penicillin-resistant pneumococci is increasing worldwide. Methods for susceptibility testing, as well as in vitro susceptibility of penicillin-susceptible and -resistant strains to new and existing agents (including oral and parenteral streptogramins), are described. For all specimens except CSF, oxa...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199600511-00003
更新日期:1996-01-01 00:00:00
abstract::Eluxadoline (Truberzi®) is an orally administered, minimally absorbed agent that acts locally in the gastrointestinal tract as a mixed µ-opioid receptor agonist and δ-opioid receptor antagonist. The randomized, double-blind, placebo-controlled, multinational, phase 3 IBS-3001 and IBS-3002 trials examined the efficacy ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0756-7
更新日期:2017-06-01 00:00:00
abstract::Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01276-1
更新日期:2020-03-01 00:00:00
abstract::Pharmacotherapy for the management of obesity is primarily aimed at weight loss, weight loss maintenance and risk reduction, and has included thyroid hormone, amphetamines, phentermine, amfepramone (diethylpropion), phenylpropanolamine, mazindol, fenfluramines and, more recently, sibutramine and orlistat. These agents...
journal_title:Drugs
pub_type: 杂志文章,meta分析,评审
doi:10.2165/00003495-200565100-00006
更新日期:2005-01-01 00:00:00
abstract::The bacteria most commonly responsible for early-onset (materno-fetal) infections in neonates are group B streptococci, enterococci, Enterobacteriaceae and Listeria monocytogenes. Coagulase-negative staphylococci, particularly Staphylococcus epidermidis, are the main pathogens in late-onset (nosocomial) infections, es...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199958030-00003
更新日期:1999-09-01 00:00:00
abstract::Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t½ of approximately 24 h and unique pharmacok...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01086-0
更新日期:2019-05-01 00:00:00
abstract::Because platelets are so important in thrombus formation, drugs which inhibit platelet function (the 'antiplatelet drugs') have considerable potential as antithrombotic agents. Among the antiplatelet drugs, only aspirin, sulphinpyrazone, dipyridamole, hydroxychloroquine, and clofibrate have had wide clinical trial. Th...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197918060-00002
更新日期:1979-12-01 00:00:00
abstract::Administration of unopposed postmenopausal estrogen therapy protects against coronary heart disease (CHD) in women. This is mediated, in part, through beneficial effects on lipid and lipoprotein metabolism. Fewer data are available with regard to CHD risk reduction when a progesterone is required in addition to estrog...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199400472-00005
更新日期:1994-01-01 00:00:00
abstract::Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU). Large, well designed trials indicate that levocetiri...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666070-00017
更新日期:2006-01-01 00:00:00
abstract::Opioid dependence, manifesting as addiction to heroin and pharmaceutical opioids is increasing. Internationally, there are an estimated 15.6 million illicit opioid users. The global economic burden of opioid dependence is profound both in terms of HIV and hepatitis C virus transmission, direct healthcare costs, and in...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11597520-000000000-00000
更新日期:2012-01-22 00:00:00
abstract::With its approval more than 15 years ago, subcutaneous etanercept (Enbrel(®)) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult pati...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0258-9
更新日期:2014-08-01 00:00:00
abstract::Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in subcutaneous tissue from...
journal_title:Drugs
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验,评审
doi:10.2165/00003495-200363160-00007
更新日期:2003-01-01 00:00:00
abstract::Antibacterial activities of cefotaxime and its major metabolite, desacetylcefotaxime, against 178 strains (of 10 species) were assessed in terms of minimum inhibitory concentrations (MIC50 and MIC80), and were compared with those of cefoperazone and ceftazidime. The activity of desacetylcefotaxime was several times le...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198800352-00013
更新日期:1988-01-01 00:00:00
abstract::A once-daily preservative-free fixed combination ophthalmic solution containing tafluprost 0.0015 % and timolol 0.5 % (hereafter referred to as tafluprost/timolol) [Taptiqom(®)] has been developed to lower intraocular pressure (IOP) whilst avoiding damage to the ocular surface associated with preservatives such as ben...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0476-9
更新日期:2015-10-01 00:00:00
abstract::The antihypertensive and vasodilator effects of felodipine, a new calcium antagonist of the dihydropyridine group, were examined in 15 patients with moderate to severe hypertension. Flow was measured simultaneously at the calf and finger using a venous occlusion ECG-triggered plethysmograph. Measurements were made at ...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198500292-00024
更新日期:1985-01-01 00:00:00
abstract::Alopecia areata (AA) is an autoimmune condition that affects up to 2% of the general population. Currently available treatment options for AA are of limited efficacy and can be associated with adverse effects. The advancement in understanding of the genetic and molecular mechanisms of AA has led to the development of ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01293-0
更新日期:2020-05-01 00:00:00
abstract::Biologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly targeted, efficacious, and represent an increasingly important part of physicians' armamentaria in the combat against th...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-018-1009-0
更新日期:2018-11-01 00:00:00
abstract::Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2). In the EU, lapatinib in combination with capecitabine is indicated for the treatment of women with HER2-overexpressing, advanced or metas...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11203240-000000000-00000
更新日期:2009-10-22 00:00:00
abstract::Hepatitis E accounts for the major part of enterally transmitted non-A, non-B hepatitis worldwide. Its agent, the hepatitis E virus (HEV), is a small, single-stranded RNA virus. Only one serotype of HEV is recognised. Infection results in protective immunity with long-lived neutralising antibodies. In developing count...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200464140-00002
更新日期:2004-01-01 00:00:00
abstract:UNLABELLED:Ofloxacin is an established fluoroquinolone agent which achieves good concentrations in genitourinary tract tissues and fluids. It has good in vitro activity against most Enterobacteriaceae, Staphylococcus saprophyticus, methicillin-susceptible S. aureus, Neisseria gonorrhoeae, Chlamydia trachomatis and Haem...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199856050-00015
更新日期:1998-11-01 00:00:00